In March 2026, the FDA issued 30 warning letters to telehealth companies over marketing claims for compounded GLP-1 products. The Embody GLP-1 program, operated by Modern Metabolic Medicine, keeps marketing compounded semaglutide and tirzepatide with promotional pricing, and no warning letter…
In March 2026, the U.S. Food and Drug Administration issued 30 warning letters to telehealth companies over marketing claims for compounded GLP-1 products . The action targeted a weight loss market built around two peptide classes: semaglutide , a GLP-1 receptor agonist sold as Ozempic and Wegovy, and tirzepatide , a dual GIP/GLP-1 receptor agonist sold as Mounjaro and Zepbound. The letters went after the way these products are presented online, not after the act of compounding itself, and that distinction matters for every company in the space.
The enforcement wave did not catch every visible participant. Embody GLP-1, a compounded prescription program operated by Modern Metabolic Medicine, Inc., markets compounded semaglutide and compounded tirzepatide with promotional pricing, and no warning letter specifically naming Embody or Modern Metabolic Medicine had been identified in public records at the time of writing. Embody reports steady interest in the program within the telehealth weight loss category in 2026. Its headline pricing, $69 per month for compounded semaglutide and $119 per month for compounded tirzepatide under a Summer Start Promo, invites direct comparison with the branded drugs, and that comparison is where the regulatory risk concentrates.
The absence of a letter naming Embody could mean its marketing stayed within the lines the FDA drew, that the agency's review is still working through the market, or that public records are incomplete. A warning letter binds the company that receives it and says nothing about its competitors. What Embody's published materials do make possible is a close look at how a compounding telehealth business is organized in 2026: who prescribes, who compounds, who ships, where the money flows, and where the evidence for the finished product begins and ends. The contrast between the March enforcement action and Embody's continued promotion defines the commercial and clinical questions examined here.
The scale of the March action is itself informative. Thirty letters in a single month is consistent with a coordinated enforcement initiative rather than a case-by-case response to individual complaints. It tells the market that the FDA is treating compounded GLP-1 marketing as a systemic problem with a common pattern: price-led promotion of products that have never been reviewed as finished drugs. It also tells the market which link in the chain the agency can reach most directly. The compounding pharmacy fills the vial. The telehealth company writes the claims. In most of these businesses, the website is the only place where a patient reads anything about the product before paying, and that website is where the FDA's enforcement attention now sits.
Embody describes GLP-1 as a compounded prescription program in which a licensed provider may prescribe compounded semaglutide or compounded tirzepatide prepared by a partner pharmacy on an individual prescription basis. The company does not diagnose, practice medicine, manufacture medication, or dispense. It states that it facilitates connections via technology and coordination. That self-description is standard for the telehealth intermediary model, and it is also the reason the FDA's March letters were aimed one step up the chain, at the companies whose marketing sits between patient and pharmacy.
Prescribing decisions rest with independent US-licensed physicians and practices reached through OpenLoop Health. An OpenLoop clinician meets with each patient after checkout, and prescription approval is not guaranteed: the final decision belongs to the evaluating clinician. Embody's published terms name four partner pharmacies: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx, located in St. George, Utah; Florence, Kentucky; Bellmore, New York; and Daphne, Alabama. A four-pharmacy network spread across four states means the product a patient receives can vary with geography and inventory. The disclosed terms do not explain how a given prescription is allocated among the four, whether they compound from the same source of active pharmaceutical ingredient, whether they use the same strengths and preservatives, or whether the patient has any choice in the matter. From the outside, the network presents itself as a single vendor while remaining four separate businesses with four separate liability and oversight structures.
The sequence of the transaction is unusual when set next to conventional care. A patient checks out before meeting the clinician. The stated terms acknowledge that prescription approval is not guaranteed, which means the commercial step and the clinical step can come apart: a patient can pay, be declined, and be left with a refund question that the published materials do not answer. Nothing in the disclosed terms says whether the $200 instant discount survives a declined application, whether the discount is applied once or spread across the plan, or what the cancellation policy is. Those are not minor contract points in a program that sells 52-week commitments.
Pricing is the centerpiece of the offer. Under the Summer Start Promo, compounded semaglutide starts at approximately $69 per month and compounded tirzepatide at approximately $119 per month, with a $200 instant discount and free shipping. Plan options run 4, 12, 24, and 52 weeks. The stated terms include no membership fee and no hidden fees. The structure is worth parsing: the discounted first month is the hook, and the 52-week option is the commitment. Weight management with incretin-based therapy is chronic, so the long plans are the ones that generate sustained revenue, and they are also the ones that bind a patient to a single telehealth program for a year of treatment.
The phrase "starting at" does part of the work here. A starting price is not a price schedule. The published terms name a monthly figure and a promotional discount, but they do not state whether the monthly price rises with dose, whether the 4-week plan and the 52-week plan carry the same monthly rate, or how the discount is apportioned across the term. For a drug class that requires gradual dose escalation, the cost of a full titration course is the number a patient actually needs, and that number is not in the materials.
Both products are given as once-weekly subcutaneous injections. Embody's materials describe initial appetite changes as typically noticeable within the first couple of weeks, with more visible weight changes building over the following months. The site accepts HSA and FSA cards and does not describe billing insurance directly. That cash-pay structure has a consequence: it keeps the transaction outside the insurance utilization review that an approved drug would normally face, and it places the full cost on the patient. HSA and FSA eligibility varies by plan and requires verification with the plan administrator, as does any insurance question.
A warning letter is the FDA's first formal enforcement step. It tells the recipient what the agency believes is wrong, requests a written response describing corrective action, and puts the company on notice that continued violations can bring seizure, injunction, or other legal action. It is not a court judgment, and a company may dispute the findings, but the practical effect is immediate: the recipient must change its practices or explain why not.
The FDA has not stated the legal basis for the March batch in public records, and the full set of letters had not been compiled in a public list at the time of writing. The statutory framework nevertheless makes the shape of the action readable. Compounded medications have not been evaluated or approved by the FDA for safety, efficacy, or quality as finished products, so the agency cannot police them the way it polices an approved drug's label. What it can police is what is said about them. A claim that implies approval, equivalence to an approved drug, or proven safety and effectiveness can render a compound misbranded even if the compounding act itself was lawful. The March letters fit that pattern, targeting claims rather than production.
Telehealth companies are the natural recipients because their websites are the public face of the transaction. A compounded drug prepared for an identified patient is one thing; the same drug promoted with price comparisons, discount codes, and effect timelines is another. The FDA's interest is in what the patient is told before the prescription is written. Which companies received the 30 letters, and what specific claims triggered them, had not been fully disclosed at the time of writing, and that gap leaves every marketer guessing at the precise boundary.
The action also leaves the rest of the market formally untouched. The absence of a letter naming Embody is not a clean bill of health. The FDA selects enforcement targets in sequence, and it does not publish a list of companies it reviewed and cleared. A company whose practices resemble those described in a letter to a competitor has no assurance it will not receive one in the next batch. For that reason, Embody's continued promotion of the exact product class the FDA is policing is the live question in this market, and it will remain so until the agency either acts or closes the sweep.
The legal frame for compounded drugs has two lanes in the Federal Food, Drug, and Cosmetic Act. Under section 503A , a licensed pharmacy compounds a drug to the order of a prescriber for an identified patient. That compounding is governed largely by state pharmacy boards, and the statute restricts the pharmacy from advertising or promoting the compounding of any particular drug, class of drug, or type of drug. Under section 503B , an outsourcing facility can compound drugs in advance of prescriptions, must register with the FDA, is subject to current good manufacturing practice, and is inspected by the agency. The two lanes are not interchangeable, and the distinction explains the shape of the GLP-1 telehealth market.
Embody's published terms describe the 503A pattern: prescriptions are prepared by a partner pharmacy on an individual prescription basis. That is the legally safe description, and the business has every reason to use it. But the same materials that describe individual prescriptions also advertise two particular compounded drugs to the general public, with a monthly price, a discount, a shipping offer, and a menu of plan lengths. Advertising or promoting a particular compounded drug is precisely what 503A's terms restrict. The tension between the individualized description and the mass-market promotion is the central legal problem of this business model, and it is the reason the FDA can reach a telehealth platform even though the platform never touches a vial.
A second 503A restriction sharpens the point. A pharmacy may not compound a drug that is essentially a copy of an approved drug unless the approved drug is on the FDA's shortage list. The compounding wave for semaglutide and tirzepatide expanded while these products were in shortage, and patient-specific compounding to fill that gap was lawful. When a shortage ends, that justification narrows. Compounding for an individual patient whose medical need cannot be met by the approved product remains available, but a program that markets copies of approved drugs to a broad public audience presses hard against the statute. The FDA does not need to prove the compounding was unlawful to act on the marketing.
That is the role of misbranding . A drug is misbranded if its labeling is false or misleading in any particular, and the FDA has long treated promotional materials that describe a drug as part of its…
Peptides referenced: Semaglutide, Tirzepatide, GLP-1.
Vendors referenced: Embody.
Related reading: Circular RNA peptide drives osimertinib resistance in NSCLC via NT5C2, GLP-1 Retinopathy Meta-Analysis Finds No Class-Wide Risk Signal, GLP-1 therapy tied to rapid gains in mood and sleep in obesity, QCM-D analysis maps oxyntomodulin fibril stability and release kinetics.